Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial (Trials, (2022), 23, 1, (45), 10.1186/s13063-021-05968-1)

Christopher Kai Shun Leung; Seraph Tianmin Ren; Poemen Pui Man Chan; Kelvin Ho Nam Wan; Aziz Ka Wai Kam; Gilda Wing Ki Lai; Vivian Sheung Man Chiu; Match Wai Lun Ko; Cedric Ka Fai Yiu; Marco Chak Yan Yu

doi:10.1186/s13063-022-06079-1

Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial (Trials, (2022), 23, 1, (45), 10.1186/s13063-021-05968-1)

Christopher Kai Shun Leung
, Seraph Tianmin Ren
, Poemen Pui Man Chan
, Kelvin Ho Nam Wan
, Aziz Ka Wai Kam
, Gilda Wing Ki Lai
, Vivian Sheung Man Chiu
, Match Wai Lun Ko
, Cedric Ka Fai Yiu
, Marco Chak Yan Yu

Research output: Journal article publication › Comment/debate/erratum

1 Citation (Scopus)

Abstract

Following the publication of the original article [1], we were notified that the received date of the paper was 26 November 2020, and not 8 March 2021. The original article has been corrected.

Original language	English
Article number	134
Journal	Trials
Volume	23
Issue number	1
DOIs	https://doi.org/10.1186/s13063-022-06079-1
Publication status	Published - Dec 2022

ASJC Scopus subject areas

Medicine (miscellaneous)
Pharmacology (medical)

More information

10.1186/s13063-022-06079-1

Fingerprint

Dive into the research topics of 'Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial (Trials, (2022), 23, 1, (45), 10.1186/s13063-021-05968-1)'. Together they form a unique fingerprint.

Cite this

Leung, C. K. S., Ren, S. T., Chan, P. P. M., Wan, K. H. N., Kam, A. K. W., Lai, G. W. K., Chiu, V. S. M., Ko, M. W. L., Yiu, C. K. F., & Yu, M. C. Y. (2022). Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial (Trials, (2022), 23, 1, (45), 10.1186/s13063-021-05968-1). Trials, 23(1), Article 134. https://doi.org/10.1186/s13063-022-06079-1

@article{fe16ec5a1e28453c912677ad5b02dc12,

title = "Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial (Trials, (2022), 23, 1, (45), 10.1186/s13063-021-05968-1)",

abstract = "Following the publication of the original article [1], we were notified that the received date of the paper was 26 November 2020, and not 8 March 2021. The original article has been corrected.",

author = "Leung, \{Christopher Kai Shun\} and Ren, \{Seraph Tianmin\} and Chan, \{Poemen Pui Man\} and Wan, \{Kelvin Ho Nam\} and Kam, \{Aziz Ka Wai\} and Lai, \{Gilda Wing Ki\} and Chiu, \{Vivian Sheung Man\} and Ko, \{Match Wai Lun\} and Yiu, \{Cedric Ka Fai\} and Yu, \{Marco Chak Yan\}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1186/s13063-022-06079-1",

language = "English",

volume = "23",

journal = "Trials",

issn = "1745-6215",

publisher = "BioMed Central Ltd.",

number = "1",

}

Leung, CKS, Ren, ST, Chan, PPM, Wan, KHN, Kam, AKW, Lai, GWK, Chiu, VSM, Ko, MWL, Yiu, CKF & Yu, MCY 2022, 'Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial (Trials, (2022), 23, 1, (45), 10.1186/s13063-021-05968-1)', Trials, vol. 23, no. 1, 134. https://doi.org/10.1186/s13063-022-06079-1

Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial (Trials, (2022), 23, 1, (45), 10.1186/s13063-021-05968-1). / Leung, Christopher Kai Shun; Ren, Seraph Tianmin; Chan, Poemen Pui Man et al.
In: Trials, Vol. 23, No. 1, 134, 12.2022.

Research output: Journal article publication › Comment/debate/erratum

TY - JOUR

T1 - Correction to

T2 - Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial (Trials, (2022), 23, 1, (45), 10.1186/s13063-021-05968-1)

AU - Leung, Christopher Kai Shun

AU - Ren, Seraph Tianmin

AU - Chan, Poemen Pui Man

AU - Wan, Kelvin Ho Nam

AU - Kam, Aziz Ka Wai

AU - Lai, Gilda Wing Ki

AU - Chiu, Vivian Sheung Man

AU - Ko, Match Wai Lun

AU - Yiu, Cedric Ka Fai

AU - Yu, Marco Chak Yan

PY - 2022/12

Y1 - 2022/12

N2 - Following the publication of the original article [1], we were notified that the received date of the paper was 26 November 2020, and not 8 March 2021. The original article has been corrected.

AB - Following the publication of the original article [1], we were notified that the received date of the paper was 26 November 2020, and not 8 March 2021. The original article has been corrected.

UR - https://www.scopus.com/pages/publications/85124500326

U2 - 10.1186/s13063-022-06079-1

DO - 10.1186/s13063-022-06079-1

M3 - Comment/debate/erratum

C2 - 35144657

AN - SCOPUS:85124500326

SN - 1745-6215

VL - 23

JO - Trials

JF - Trials

IS - 1

M1 - 134

ER -

Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial (Trials, (2022), 23, 1, (45), 10.1186/s13063-021-05968-1)

Abstract

ASJC Scopus subject areas

More information

Other files and links

Fingerprint

Cite this